Free Trial

Edesa Biotech (EDSA) Competitors

Edesa Biotech logo
$1.72 +0.01 (+0.88%)
As of 03:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EDSA vs. PLUR, FBRX, INAB, IBIO, TRAW, PULM, NXTC, CARA, COCP, and TENX

Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Pluri (PLUR), Forte Biosciences (FBRX), IN8bio (INAB), iBio (IBIO), Traws Pharma (TRAW), Pulmatrix (PULM), NextCure (NXTC), Cara Therapeutics (CARA), Cocrystal Pharma (COCP), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry.

Edesa Biotech vs.

Edesa Biotech (NASDAQ:EDSA) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Edesa Biotech has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Pluri has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Edesa Biotech has a net margin of 0.00% compared to Pluri's net margin of -4,184.28%. Edesa Biotech's return on equity of -164.32% beat Pluri's return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -164.32% -105.68%
Pluri -4,184.28%-917.18%-82.85%

In the previous week, Pluri had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Pluri and 0 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.00 equaled Pluri'saverage media sentiment score.

Company Overall Sentiment
Edesa Biotech Neutral
Pluri Neutral

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by company insiders. Comparatively, 10.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Edesa Biotech has higher earnings, but lower revenue than Pluri. Edesa Biotech is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$6.17M-$1.93-0.89
Pluri$330K73.19-$20.89M-$6.03-0.72

Edesa Biotech presently has a consensus price target of $21.00, suggesting a potential upside of 1,124.49%. Given Edesa Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Edesa Biotech is more favorable than Pluri.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pluri
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Edesa Biotech received 27 more outperform votes than Pluri when rated by MarketBeat users.

CompanyUnderperformOutperform
Edesa BiotechOutperform Votes
27
77.14%
Underperform Votes
8
22.86%
PluriN/AN/A

Summary

Edesa Biotech beats Pluri on 9 of the 15 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDSA vs. The Competition

MetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.95M$6.58B$5.39B$9.13B
Dividend YieldN/A2.96%5.37%4.00%
P/E Ratio-0.8910.0188.8317.53
Price / SalesN/A335.611,282.2680.28
Price / CashN/A22.6336.6032.90
Price / Book2.815.084.964.69
Net Income-$6.17M$154.90M$117.89M$224.57M
7 Day Performance7.87%2.59%2.75%3.33%
1 Month Performance-0.87%1.52%3.63%5.33%
1 Year Performance-60.67%5.49%27.27%22.97%

Edesa Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDSA
Edesa Biotech
3.3221 of 5 stars
$1.72
+0.9%
$21.00
+1,124.5%
-60.8%$5.95MN/A-0.8920Positive News
PLUR
Pluri
0.1349 of 5 stars
$4.23
-0.2%
N/A-9.2%$23.52M$598,000.00-0.70150News Coverage
FBRX
Forte Biosciences
3.3798 of 5 stars
$16.00
-10.0%
$23.58
+47.4%
+55,870.1%$23.39MN/A-0.985Analyst Forecast
News Coverage
INAB
IN8bio
3.584 of 5 stars
$0.32
-1.9%
$7.75
+2,344.8%
-77.9%$22.98MN/A-0.4220
IBIO
iBio
1.9136 of 5 stars
$2.48
-2.7%
$4.30
+73.4%
N/A$22.69M$175,000.000.00100Positive News
TRAW
Traws Pharma
0.5442 of 5 stars
$7.33
-9.1%
N/AN/A$22.18M$226,000.00-0.0517Gap Down
PULM
Pulmatrix
0.9708 of 5 stars
$5.99
-0.3%
N/A+245.2%$21.88M$10.01M-2.2720Positive News
NXTC
NextCure
4.2203 of 5 stars
$0.78
-2.6%
$4.00
+414.1%
-30.2%$21.79MN/A-0.3790
CARA
Cara Therapeutics
4.0328 of 5 stars
$4.66
-1.9%
$27.84
+497.4%
-31.4%$21.29M$8.69M-2.6680
COCP
Cocrystal Pharma
2.5895 of 5 stars
$2.08
-5.9%
$7.00
+236.5%
+22.2%$21.16MN/A-1.1210Positive News
Gap Down
TENX
Tenax Therapeutics
2.0125 of 5 stars
$6.16
-1.3%
$16.00
+159.7%
-35.1%$21.00MN/A0.009

Related Companies and Tools


This page (NASDAQ:EDSA) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners